Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Furst

Showing results (1-10 of 477) with videos related to

Pageof 48
Sort By:
Clinical Therapeutics|April 13, 2005
Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritisDaniel E Furst
Seminars in Arthritis and Rheumatism|July 16, 2008
Serum immunoglobulins and risk of infection: how low can you go?Daniel E Furst
Seminars in Arthritis and Rheumatism|January 2, 2009
The risk of infections with biologic therapies for rheumatoid arthritisDaniel E Furst
Clinical and Experimental Rheumatology|June 26, 2010
Development of TNF inhibitor therapies for the treatment of rheumatoid arthritisDaniel E Furst
The Journal of Rheumatology|August 4, 2004
Observational cohort studies and well controlled clinical trials--we need them both!Daniel E Furst
Current Opinion in Rheumatology|May 1, 2002
Stem cell transplantation for autoimmune disease: progress and problemsDaniel E Furst
The Journal of Rheumatology|September 1, 2004
Window of opportunityDaniel E Furst
Nature Clinical Practice. Rheumatology|February 5, 2009
Certolizumab pegol--what role does this new TNF inhibitor have in the treatment of RA?Daniel E Furst
Arthritis and Rheumatism|June 4, 2005
Measuring the impact of managed care plans on the use of biologicsDaniel E Furst
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|December 17, 2008
Comment on Furst's Editorial: Postmarketing Surveys: Up Sides and Down Sides: In Reply to "Comment on Furst Editorial: Postmarketing Surveys, Upsides and Downsides"Daniel E Furst
Pageof 48

Showing results (1-10 of 477) with videos related to

Sort By:
Pageof 48
Clinical Therapeutics|April 13, 2005
Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritisDaniel E Furst
Seminars in Arthritis and Rheumatism|July 16, 2008
Serum immunoglobulins and risk of infection: how low can you go?Daniel E Furst
Seminars in Arthritis and Rheumatism|January 2, 2009
The risk of infections with biologic therapies for rheumatoid arthritisDaniel E Furst
Clinical and Experimental Rheumatology|June 26, 2010
Development of TNF inhibitor therapies for the treatment of rheumatoid arthritisDaniel E Furst
The Journal of Rheumatology|August 4, 2004
Observational cohort studies and well controlled clinical trials--we need them both!Daniel E Furst
Current Opinion in Rheumatology|May 1, 2002
Stem cell transplantation for autoimmune disease: progress and problemsDaniel E Furst
The Journal of Rheumatology|September 1, 2004
Window of opportunityDaniel E Furst
Nature Clinical Practice. Rheumatology|February 5, 2009
Certolizumab pegol--what role does this new TNF inhibitor have in the treatment of RA?Daniel E Furst
Arthritis and Rheumatism|June 4, 2005
Measuring the impact of managed care plans on the use of biologicsDaniel E Furst
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|December 17, 2008
Comment on Furst's Editorial: Postmarketing Surveys: Up Sides and Down Sides: In Reply to "Comment on Furst Editorial: Postmarketing Surveys, Upsides and Downsides"Daniel E Furst
Pageof 48